{
BioMarin Pharmaceutical Inc.

Companies

}
Symbol BMRN
Name BioMarin Pharmaceutical Inc.
Currency USD
Sector Health Care
IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
Industry Biotechnology
Market NASDAQ Global Select
Country United States
State CA
City San Rafael
Zipcode 94901
Website http://www.biomarin.com
Track all markets on TradingView
BioMarin price target increased as solid quarter boosts investor confidence
UBS has raised its price target for BioMarin (BMRN) to $106 from $104, maintaining a Buy rating following a strong quarterly performance and improved guidance. The firm believes the enzyme replacement therapy business justifies the current share price and sees potential in BMN333, set to enter clinical trials in early 2025, as a key value driver for expanding indications.
@YahooFinance
United States Dollar BioMarin Pharmaceutical Inc. USA
TradFi, Market Report
12:33 31.10.2024
vanguard and other investors increase stakes in biomarin pharmaceutical stock
Vanguard Group Inc. now holds 18,117,108 shares of BioMarin Pharmaceutical, valued at $1.58 billion, after acquiring 67,046 additional shares. Other institutional investors, including Avoro Capital Advisors and Dimensional Fund Advisors, have also increased their stakes, with 98.71% of the stock owned by such entities. BioMarin's stock has a "Moderate Buy" rating, with a consensus price target of $96.52, despite recent trading down 4.1% to $67.02.
MarketBeat
BioMarin Pharmaceutical Inc. USA
TradFi, Market Report
15:40 30.10.2024
biomarin reports strong revenue growth driven by pediatric dwarfism treatment
BioMarin Pharmaceutical reported a strong Q3 performance, with total revenue reaching $745.74 million, a 28% increase year-over-year. The growth was driven by Voxzogo, a treatment for pediatric dwarfism, which saw a 54% rise in product revenue to $190 million, benefiting over 3,800 children. Net income surged to $106 million, more than double from the previous year, while operating expenses rose to $631.84 million. CEO Alexander Hardy expressed optimism about the company's new strategy focused on innovation and growth.
The North Bay Business Journal
United States Dollar BioMarin Pharmaceutical Inc. USA Alexander Hardy
Healthcare, Market Report
00:54 30.10.2024
biopharma companies announce significant layoffs amid restructuring and disappointing trial results
Several biopharma companies are implementing significant layoffs as part of restructuring efforts to extend their cash runways. Ovid, Lexicon Pharmaceuticals, Acelyrin, and FibroGen are among those reducing their workforce, with layoffs ranging from 33% to 75% of their staff. These moves follow disappointing clinical trial results and strategic shifts in focus, aiming to optimize resources and ensure continued funding for research and development.
biospace.com
Bayer AG Lexicon Pharmaceuticals, Inc. Exscientia plc BioMarin Pharmaceutical Inc. Takeda iP Holdings Co.,Ltd. Joe Biden Jason Kelly Donald Trump Bill Anderson Shawn Iadonato Show more
Healthcare, News Article
09:00 23.10.2024
Pfizer's Hympavzi receives FDA approval for hemophilia treatment options
The FDA has approved Pfizer's Hympavzi for treating hemophilia A and B in patients aged 12 and older without inhibitors. This weekly injection reduces the activity of tissue factor pathway inhibitor, enhancing blood clotting. Hympavzi offers a new treatment option alongside gene therapies and other factor replacement drugs, showing superior results in lowering bleeding rates.
BioPharma Dive
United States Dollar Pfizer Inc. CSL Behring BioMarin Pharmaceutical Inc. Hoffmann-La Roche AG Sanofi USA Starboard Value Aamir Malik Show more
Healthcare, News Article
13:45 14.10.2024
Trending
Subcategory:
Cryptocurrency Markets Stock Market Updates Cryptocurrency Trends Corporate Responsibility & ESG Market Sentiment Analysis Central Bank Actions Decentralized Finance (DeFi) Innovations Cryptocurrency & Blockchain Regulations Banking Regulations Tokenomics and Crypto Economics Cryptocurrency Regulations Anti-Money Laundering (AML) Regulations Market Analysis and Predictions Funding Rounds & Investments Mergers & Acquisitions Cryptocurrency Developments SEC & Financial Compliance Inflation Rates & CPI Data Real Estate Investments Shareholder Activism
Countries:
USA CHE JPN AUS CAN IND GBR DEU AUT CHN HKG RUS LIE SAU BHR FRA ARG COL FIN NLD
Companies:
Coinbase Global, Inc. Ripples USD Solana USD BlackRock, Inc. Ethereum USD Credit Suisse Real Estate Fund Siat NVIDIA Corporation Cardano USD Tesla, Inc. Apple Inc. MicroStrategy Incorporated Amazon.com, Inc. Sumitomo Corp Google Inc. Bitwise Bitcoin ETF Chainlink USD Palantir Technologies Inc. Tether USDt CNY VAT Group AG Northern Star Resources Ltd
Currencies:
United States Dollar Euro Swiss Franc Japanese Yen Australian Dollar Canadian Dollar Colombian Peso Singapore Dollar Indian Rupee
People:
Ali Martinez Donald Trump Michael J. Saylor Elon Musk Karin Keller-Sutter Charles Hoskinson Bill Gates Fred Thiel Jack Dorsey Jacob King Brian Armstrong Aaron Green Gary Gensler Ueli Maurer Mario Nawfal Alan Santana Richard Schueler Roger J. Hamilton Steven Rossi Jane Dietze

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Links

Address

Waitlist

We’re granting exclusive early access to the first 500 users from december 20.

© 2024 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Save settings
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.